A Phase 3 interventional study of Ferric Maltol and Ferric Carboxy Maltose in Anemia, Iron-Deficiency, Inflammatory Bowel Disease and Crohn's Disease, sponsored by Shield Therapeutics. Completed at 44 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-02.
Sponsored by Shield Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing ferric maltol in Anemia, Iron-Deficiency — none open to participants now, none under way, none of them phase 3. ferric maltol · Anemia, Iron-Deficiency.
Among the 12 studies testing ferric maltol in Anemia, Iron-Deficiency, this one has the largest enrollment, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 3rd registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →None of the 12 studies testing ferric maltol in Anemia, Iron-Deficiency is open now. The open studies under Anemia, Iron-Deficiency, anywhere →
ferric maltol: first FDA approval 2019 (ACCRUFER), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 78 across the 12 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 4 most frequent:
Shield Therapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.
Shield Therapeutics has 8 studies filed under Anemia, Iron-Deficiency — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing ferric maltol in Anemia, Iron-Deficiency, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent maintenance of haemoglobin in subjects with Inflammatory Bowel Disease (IBD).
A phase 3b, randomized, controlled, multicentre study with oral ferric maltol or intravenous iron (FCM), for the treatment of iron deficiency anaemia in subjects with inflammatory bowel disease.
Approximately 242 eligible subjects will be randomised (1:1) to receive one of the following treatments for the duration of the study treatment period (52 weeks):
In the FCM arm IV iron treatment will be repeated if the subject is iron deficient at any of the study visits.
Subject participation in the study will consist of 3 periods:
Primary efficacy and safety of ferric maltol and Intravenous iron (ferric carboxy maltose) will be evaluated after the first 12 weeks.
End of study evaluations will occur at Week 52 or premature discontinuation.
All of the following criteria must be met to randomize a subject in the study:
Subjects must have iron deficiency anaemia defined by the following criteria:
A subject who meets any of the following criteria is not eligible for participation in the study.
Subject with anaemia due to any cause other than iron deficiency, including, but not limited to:
Variations to dosing are permitted at the discretion of the investigator so long as there is no clinical evidence or suspicion of the immunosuppressant contributing to the subject's anaemia or affecting erythropoiesis
Subject who has received prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 mg capsules to be taken orally twice a day for 52 weeks
Drug: Ferric Maltol
Administered as per the local summary of product characteristics (SPC)
Drug: Ferric Carboxy Maltose
Also known as: Feraccru, Ferric Trimaltol, ST10, ST10-01
Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12
Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (\>=12g/dL women,\>=13g/dL men) at Week 12
Time frame: Baseline to Week 12
Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12
Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (\>=12g/dL women, \>=13g/dL men) at Week 12
Time frame: Baseline to Week 12
Change in Hb Concentration From Baseline to Week 12
Change in hemoglobin concentration from baseline to Week 12.
Time frame: Baseline to Week 12
Change in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb <9.5 g/dL
Change in hemoglobin concentration from baseline to Week 12 in subjects with a baseline hemoglobin \<9.5 g/dL.
Time frame: Baseline to Week 12
Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 12
Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 12.
Time frame: Baseline to Week 12
Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 12
Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 12.
Time frame: Baseline to Week 12
Number of Subjects With Hb Concentration Within Normal Limits at Week 12
Number of subjects with Hb concentration within normal limits at Week 12 (normal limit definition: \>=12g/dL women, \>=13g/dL men)
Time frame: Baseline to Week 12
Number of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 12
Number of subjects with baseline Hb concentration \<9.5 g/dL that is within normal limits at Week 12 (normal limit definition: \>=12g/dL women, \>=13g/dL men)
Time frame: Baseline to Week 12
Proportion of Subjects Who Are Non-anaemic at 6 Months and 12 Months
Long term efficacy endpoints i.e. proportion of subjects who are non-anaemic at 6 months and 12 months (normal limit definition: \>=12g/dL women, \>=13g/dL men)
Time frame: Baseline to Month 6
Change in Hb Concentration From Baseline to Week 4
Change in hemoglobin concentration from baseline to Week 4.
Time frame: Baseline to Week 4
Change in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb <9.5 g/dL
Change in hemoglobin concentration from baseline to Week 4 in subjects with a baseline hemoglobin \<9.5 g/dL.
Time frame: Baseline to Week 4
Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 12
Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 12.
Time frame: Baseline to Week 12
Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 12
Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 12.
Time frame: Baseline to Week 12
Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 4
Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 4.
Time frame: Baseline to Week 4
Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 4
Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 4.
Time frame: Baseline to Week 4
Number of Subjects With Hb Concentration Within Normal Limits at Week 4
Number of subjects with Hb concentration within normal limits at Week 4 (normal limit definition: \>=12g/dL women, \>=13g/dL men)
Time frame: Baseline to Week 4
Number of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 4
Number of subjects with baseline Hb concentration \<9.5 g/dL that is within normal limits at Week 4 (normal limit definition: \>=12g/dL women, \>=13g/dL men)
Time frame: Baseline to Week 4
Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 4
Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 4.
Time frame: Baseline to Week 4
Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 4
Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 4
Time frame: Baseline to Week 4
Change From Baseline Physical Component and Mental Component Score
A multipurpose, proprietary health survey with 36 questions. It was constructed to survey health status in the Medical Outcomes Study and designed for use in clinical practice and research \& general population surveys. The SF-36 includes one multi-item scale that assesses 8 health components: Physical Functioning Component; Social Functioning Component; Role-Physical Component; Bodily Pain Component; Mental Health Component; Role-Emotional Component; Vitality Component; \& General Health Component. These 8 health component scales can be further summarised into 2 summary scores, the Mental Component Score \& the Physical Component Score where higher values mean a better outcome. Both scales range from 0 to 100, where higher scores indicate better health status. The survey will be administered at study visits as indicated in the schedule of assessments, commencing pre-randomization at Visit 2. The survey will be completed by the subjects in their native language.
Time frame: Baseline to Week 52 (LOCF)
Number of Patients With Treatment-emergent Adverse Events (AEs)
Number of Patients with Treatment-emergent Adverse Events (AEs).
Time frame: Baseline to Week 52
Number of Patients With Treatment-emergent Serious Adverse Events (SAEs)
Number of Patients with Treatment-emergent Serious Adverse Events (SAEs).
Time frame: Baseline to Week 52
| Milestone | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Started | 125 | 125 |
| Received treatment | 127 | 120 |
| Completed | 93 | 106 |
| Not completed | 32 | 19 |
| Withdrew: Adverse event | 10 | 2 |
| Withdrew: Lost to follow-up | 7 | 6 |
| Withdrew: Withdrawal by subject | 5 | 5 |
| Withdrew: Physician decision | 4 | 1 |
| Withdrew: Hb ≤7.5 g/dl | 0 | 2 |
| Withdrew: Blood transfusion for any reason | 0 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Tsat above 60% or a ferritin above 800 m | 1 | 0 |
| Withdrew: None of above or not recorded | 3 | 2 |
Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (\>=12g/dL women,\>=13g/dL men) at Week 12
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 84 | 105 |
| Non-responder | 41 | 20 |
Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (\>=12g/dL women, \>=13g/dL men) at Week 12
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 53 | 75 |
| Non-responder | 25 | 13 |
Change in hemoglobin concentration from baseline to Week 12.
| g/dL | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Change in Hb Concentration From Baseline to Week 12 | 2.45 ± 1.449 | 3.04 ± 1.576 |
Change in hemoglobin concentration from baseline to Week 12 in subjects with a baseline hemoglobin \<9.5 g/dL.
| g/dL | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Change in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb <9.5 g/dL | 2.83 ± 1.493 | 4.18 ± 1.686 |
Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 12.
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 107 | 111 |
| Non-responder | 18 | 14 |
Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 12.
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 35 | 32 |
| Non-responder | 3 | 3 |
Number of subjects with Hb concentration within normal limits at Week 12 (normal limit definition: \>=12g/dL women, \>=13g/dL men)
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 69 | 101 |
| Non-responder | 56 | 24 |
Number of subjects with baseline Hb concentration \<9.5 g/dL that is within normal limits at Week 12 (normal limit definition: \>=12g/dL women, \>=13g/dL men)
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 12 | 28 |
| Non-responder | 26 | 7 |
Long term efficacy endpoints i.e. proportion of subjects who are non-anaemic at 6 months and 12 months (normal limit definition: \>=12g/dL women, \>=13g/dL men)
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| week 24 — Non-anaemic | 52 | 58 |
| week 24 — Anaemic | 28 | 27 |
| week 52 — Non-anaemic | 37 | 36 |
| week 52 — Anaemic | 24 | 20 |
Change in hemoglobin concentration from baseline to Week 4.
| g/dL | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Change in Hb Concentration From Baseline to Week 4 | 1.27 ± 0.974 | 2.19 ± 1.133 |
Change in hemoglobin concentration from baseline to Week 4 in subjects with a baseline hemoglobin \<9.5 g/dL.
| g/dl | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Change in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb <9.5 g/dL | 1.35 ± 0.993 | 2.99 ± 1.092 |
Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 12.
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 76 | 96 |
| Non-responder | 49 | 29 |
Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 12.
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 26 | 30 |
| Non-responder | 12 | 5 |
Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 4.
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 75 | 105 |
| Non-responder | 50 | 20 |
Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 4.
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 22 | 31 |
| Non-responder | 14 | 2 |
Number of subjects with Hb concentration within normal limits at Week 4 (normal limit definition: \>=12g/dL women, \>=13g/dL men)
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 31 | 60 |
| Non-responder | 94 | 65 |
Number of subjects with baseline Hb concentration \<9.5 g/dL that is within normal limits at Week 4 (normal limit definition: \>=12g/dL women, \>=13g/dL men)
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 2 | 15 |
| Non-responder | 36 | 20 |
Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 4.
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 26 | 75 |
| Non-responder | 99 | 50 |
Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 4
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Responder | 5 | 28 |
| Non-responder | 33 | 7 |
A multipurpose, proprietary health survey with 36 questions. It was constructed to survey health status in the Medical Outcomes Study and designed for use in clinical practice and research \& general population surveys. The SF-36 includes one multi-item scale that assesses 8 health components: Physical Functioning Component; Social Functioning Component; Role-Physical Component; Bodily Pain Component; Mental Health Component; Role-Emotional Component; Vitality Component; \& General Health Component. These 8 health component scales can be further summarised into 2 summary scores, the Mental Component Score \& the Physical Component Score where higher values mean a better outcome. Both scales range from 0 to 100, where higher scores indicate better health status. The survey will be administered at study visits as indicated in the schedule of assessments, commencing pre-randomization at Visit 2. The survey will be completed by the subjects in their native language.
| score on a scale | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Physical component score | 3.0 ± 7.62 | 2.5 ± 7.52 |
| Mental component score | 3.3 ± 8.32 | 2.6 ± 7.60 |
Number of Patients with Treatment-emergent Adverse Events (AEs).
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Number of Patients With Treatment-emergent Adverse Events (AEs) | 75 | 43 |
Number of Patients with Treatment-emergent Serious Adverse Events (SAEs).
| Participants | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Number of Patients With Treatment-emergent Serious Adverse Events (SAEs) | 9 | 3 |
Collected over The analysis of AEs focuses on TEAEs, which were defined as any AE that occurred on or worsened after the first dose of IMP and up to 14 days after the last dose of IMP (week 52 if study completed). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Ferric Iron Compound | 1/127 (0.8%) | 12/127 (9.4%) | 75/127 (59.1%) |
| Intravenous Iron | 0/120 (0%) | 4/120 (3.3%) | 43/120 (35.8%) |
| Event | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Gastrointestinal disordersGastrointestinal disorders | 3/127 | 2/120 |
| Infections and infestationsInfections and infestations | 3/127 | 1/120 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 2/127 | 0/120 |
| Cardiac disordersCardiac disorders | 2/127 | 0/120 |
| Neoplasms benign, malignant and unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/127 | 1/120 |
| Blood and lymphatic system disordersBlood and lymphatic system disorders | 1/127 | 0/120 |
| General disorders and administration site conditionsGeneral disorders | 1/127 | 0/120 |
| Psychiatric disordersPsychiatric disorders | 1/127 | 0/120 |
| Event | Oral Ferric Iron Compound | Intravenous Iron |
|---|---|---|
| Gastrointestinal disordersGastrointestinal disorders | 40/127 | 15/120 |
| Infections and infestationsInfections and infestations | 29/127 | 22/120 |
| Abdominal painGeneral disorders | 12/127 | 15/120 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 11/127 | 2/120 |
| NasopharyngitisInfections and infestations | 10/127 | 4/120 |
| General disorders and administration site conditionsGeneral disorders | 9/127 | 6/120 |
| Nervous system disordersNervous system disorders | 9/127 | 4/120 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 9/127 | 4/120 |
| Abdominal pain upperGastrointestinal disorders | 7/127 | 2/120 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 7/127 | 2/120 |
ITT
| Age, Continuous(years) | Oral Ferric Iron Compound | Intravenous Iron | Total |
|---|---|---|---|
| Mean | 40.0 ± 14.58 | 40.4 ± 15.54 | 40.2 ± 15.04 |
| Age, Customized(years) | Oral Ferric Iron Compound | Intravenous Iron | Total |
|---|---|---|---|
| Age range | 40.0 (18 to 81) | 40.4 (19 to 77) | 40.2 (18 to 81) |
| Sex: Female, Male(Participants) | Oral Ferric Iron Compound | Intravenous Iron | Total |
|---|---|---|---|
| Female | 68 | 77 | 145 |
| Male | 57 | 48 | 105 |
| Race/Ethnicity, Customized(Participants) | Oral Ferric Iron Compound | Intravenous Iron | Total |
|---|---|---|---|
| Race — American Indian/Alaskan Native | 0 | 1 | 1 |
| Race — Asian | 0 | 2 | 2 |
| Race — Black/African American | 6 | 3 | 9 |
| Race — White | 110 | 111 | 221 |
| Race — Other | 8 | 8 | 16 |
| Race — Native American/Pacific Islander | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Oral Ferric Iron Compound | Intravenous Iron | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 15 | 20 | 35 |
| Ethnicity — Not Hispanic or Latino | 99 | 94 | 193 |
| Ethnicity — Not Reported | 8 | 8 | 16 |
| Ethnicity — Unknown | 3 | 3 | 6 |
| Fertility status (females)(Participants) | Oral Ferric Iron Compound | Intravenous Iron | Total |
|---|---|---|---|
| Sterile | 8 | 6 | 14 |
| Post-menopausal | 13 | 16 | 29 |
| Potentially fertile | 46 | 54 | 100 |
| Not available | 1 | 1 | 2 |
| Screening Hb for randomisation(Participants) | Oral Ferric Iron Compound | Intravenous Iron | Total |
|---|---|---|---|
| <10 g/dL Female or <11 g/dL Male | 67 | 67 | 134 |
| ≥10 g/dL Female or ≥11 g/dL Male | 58 | 58 | 116 |
| Baseline Hb(Participants) | Oral Ferric Iron Compound | Intravenous Iron | Total |
|---|---|---|---|
| <9.5 g/dL | 38 | 35 | 73 |
| ≥9.5 g/dL | 87 | 90 | 177 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2016 to primary completion in Oct 2018, 33 months.
Results were first posted in Feb 2020, 1 year 4 months after primary completion.
Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 33 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric maltol
Shield Therapeutics